|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.10 SEK | +5.76% |
|
+11.31% | -15.49% |
| 07-20 | SynAct Pharma Draws SEK50 Million from New Financing Facility | MT |
| 07-20 | Synact Pharma secures access to financing of up to €9.0m | FW |
Company Valuation: SynAct Pharma AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,703 | 2,416 | 314.1 | 416.8 | 1,205 | 1,070 | - | - |
| Change | - | -34.75% | -87% | 32.69% | 189.2% | -11.26% | - | - |
| Enterprise Value (EV) 1 | 3,703 | 2,416 | 314.1 | 370 | 1,152 | 1,052 | 1,094 | 1,070 |
| Change | - | -34.75% | -87% | 17.8% | 211.31% | -8.66% | 4.02% | -2.27% |
| P/E | -53.1x | -22.6x | -1.33x | -4.31x | -10.4x | -12.8x | -25.1x | - |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.7x | -0x | 0.1x | -2.4x | 0.4x | 0.5x | - |
| Capitalization / Revenue | - | - | - | - | - | 7.71x | 50.6x | 14x |
| EV / Revenue | - | - | - | - | - | 7.58x | 51.7x | 14x |
| EV / EBITDA | - | - | -1.4x | -4.11x | -9.88x | 21.8x | -36.7x | 39.8x |
| EV / EBIT | - | - | -1.4x | -4.11x | -9.88x | 21.9x | -36.5x | 39.8x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.68 | -3.6 | -6.64 | -2.08 | -2.17 | -1.49 | -0.76 | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | 138.8 | 21.15 | 76.3 |
| EBITDA 1 | - | - | -224.5 | -89.98 | -116.5 | 48.28 | -29.82 | 26.9 |
| EBIT 1 | - | - | -224.5 | -89.98 | -116.5 | 48.02 | -29.96 | 26.9 |
| Net income 1 | -69.3 | -99.2 | -215.8 | -82.4 | -110.8 | 52.18 | -26.04 | 26.9 |
| Net Debt 1 | - | - | - | -46.75 | -53.41 | -17.48 | 24.86 | - |
| Reference price 2 | 142.40 | 81.50 | 8.83 | 8.96 | 22.60 | 19.10 | 19.10 | 19.10 |
| Nbr of stocks (in thousands) | 26,006 | 29,648 | 35,571 | 46,487 | 53,330 | 55,998 | - | - |
| Announcement Date | 11/02/22 | 17/02/23 | 23/02/24 | 18/02/25 | 18/02/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -12.12x | 7.16x | 20.59x | - | 106M | |
| 34.19x | 11.9x | 25x | 0.6% | 1T | |
| 27.59x | 6.24x | 17.41x | 2.11% | 613B | |
| 33.42x | 7.23x | 14.91x | 2.82% | 433B | |
| 19.84x | 4.71x | 11.66x | 2.81% | 350B | |
| 21.78x | 5.64x | 14.07x | 2.85% | 292B | |
| 19.76x | 4.1x | 11.62x | 2.15% | 239B | |
| 13.29x | 4.98x | 10.27x | 3.76% | 206B | |
| 24.88x | 6.52x | 11.5x | 2.66% | 204B | |
| -47.26x | 5.67x | 31.29x | 2.51% | 163B | |
| Average | 13.54x | 6.42x | 16.83x | 2.48% | 350.06B | |
| Weighted average by Cap. | 23.92x | 7.55x | 17.90x | 2.05% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SYNACT Stock
- Valuation SynAct Pharma AB
Select your edition
All financial news and data tailored to specific country editions
